Understanding quality and equity: patient experiences with care in older adults diagnosed with hematologic malignancies.


Journal

Cancer causes & control : CCC
ISSN: 1573-7225
Titre abrégé: Cancer Causes Control
Pays: Netherlands
ID NLM: 9100846

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 26 05 2020
accepted: 09 01 2021
pubmed: 11 2 2021
medline: 28 4 2021
entrez: 10 2 2021
Statut: ppublish

Résumé

Oncology settings increasingly use patient experience data to evaluate clinical performance. Given that older patients with hematologic malignancies are a high-risk population, this study examined factors associated with patient-reported health care experiences during the first year of their cancer diagnosis. Cross-sectional study using the 2000-2015 SEER-CAHPS® data to examine patient experiences of Medicare enrollees with a primary diagnosis of leukemia or lymphoma. The primary outcomes were three CAHPS assessments: overall care, personal doctor, and health plan overall. We estimated case-mix adjusted and fully adjusted associations between factors (i.e., clinical and sociodemographic) and the CAHPS outcomes using bivariate statistical tests and multiple linear regression. The final sample included 1,151 patients, with 431 diagnosed with leukemia and 720 diagnosed with lymphoma (median time from diagnosis to survey 6 months). Patients who completed the survey further apart from the diagnosis date reported significantly higher adjusted ratings of care overall (β .39, p = .008) than those closer to diagnosis. American Indian/Alaska Native, Asian, and Pacific Islander patients had lower adjusted ratings of care overall (β - .73, p = .003) than Non-Hispanic white patients. Multimorbidity was significantly associated with higher adjusted personal doctor ratings (β .26, p = .003). Unfavorable patient experiences among older adults diagnosed with hematologic malignancies warrant targeted efforts to measure and improve care quality. Future measurement of experiences of cancer care soon after diagnosis, coupled with careful sampling of high-priority populations, will inform oncology leaders and clinicians on strategies to improve care for high-risk, high-cost populations.

Sections du résumé

BACKGROUND BACKGROUND
Oncology settings increasingly use patient experience data to evaluate clinical performance. Given that older patients with hematologic malignancies are a high-risk population, this study examined factors associated with patient-reported health care experiences during the first year of their cancer diagnosis.
METHODS METHODS
Cross-sectional study using the 2000-2015 SEER-CAHPS® data to examine patient experiences of Medicare enrollees with a primary diagnosis of leukemia or lymphoma. The primary outcomes were three CAHPS assessments: overall care, personal doctor, and health plan overall. We estimated case-mix adjusted and fully adjusted associations between factors (i.e., clinical and sociodemographic) and the CAHPS outcomes using bivariate statistical tests and multiple linear regression.
RESULTS RESULTS
The final sample included 1,151 patients, with 431 diagnosed with leukemia and 720 diagnosed with lymphoma (median time from diagnosis to survey 6 months). Patients who completed the survey further apart from the diagnosis date reported significantly higher adjusted ratings of care overall (β .39, p = .008) than those closer to diagnosis. American Indian/Alaska Native, Asian, and Pacific Islander patients had lower adjusted ratings of care overall (β - .73, p = .003) than Non-Hispanic white patients. Multimorbidity was significantly associated with higher adjusted personal doctor ratings (β .26, p = .003).
CONCLUSIONS CONCLUSIONS
Unfavorable patient experiences among older adults diagnosed with hematologic malignancies warrant targeted efforts to measure and improve care quality. Future measurement of experiences of cancer care soon after diagnosis, coupled with careful sampling of high-priority populations, will inform oncology leaders and clinicians on strategies to improve care for high-risk, high-cost populations.

Identifiants

pubmed: 33566250
doi: 10.1007/s10552-021-01395-4
pii: 10.1007/s10552-021-01395-4
pmc: PMC7946754
mid: NIHMS1674447
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

379-389

Subventions

Organisme : NCI NIH HHS
ID : P30-CA-046592
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA236621
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL146354
Pays : United States
Organisme : NHLBI NIH HHS
ID : K24 HL156896
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA046592
Pays : United States
Organisme : American Cancer Society
ID : 33507-DSCN-19-048-01-SCN

Références

Cancer. 2017 Jan 1;123(2):336-344
pubmed: 27654842
Cancer Control. 2003 Nov-Dec;10(6):469-77
pubmed: 14652523
Cancer. 2018 Aug 1;124(15):3257-3265
pubmed: 29878305
Health Serv Res. 2001 Jul;36(3):595-617
pubmed: 11482591
J Health Soc Behav. 1995 Mar;36(1):1-10
pubmed: 7738325
Health Serv Res. 2009 Apr;44(2 Pt 1):542-61
pubmed: 19040424
J Clin Oncol. 2006 Jul 1;24(19):3121-7
pubmed: 16754935
Blood. 2018 Feb 1;131(5):515-524
pubmed: 29141942
BMJ. 2009 Jun 29;338:b2393
pubmed: 19564179
Leuk Lymphoma. 2008 Jul;49(7):1352-9
pubmed: 18604724
Cancer. 2004 Oct 15;101(8):1824-34
pubmed: 15372482
Health Serv Res. 2011 Aug;46(4):1039-58
pubmed: 21306370
Leuk Lymphoma. 2009 Mar;50(3):392-400
pubmed: 19294556
Health Serv Res. 2018 Aug;53 Suppl 1:3027-3051
pubmed: 29435975
Cancer Causes Control. 2020 Jan;31(1):13-23
pubmed: 31797123
JAMA Surg. 2015 Sep;150(9):858-64
pubmed: 26108091
Health Serv Res. 2005 Dec;40(6 Pt 2):2096-119
pubmed: 16316440
Med Care Res Rev. 2014 Oct;71(5):522-54
pubmed: 25027409
Leuk Res Rep. 2016 Jun 16;6:1-7
pubmed: 27408788
J Clin Oncol. 2010 Sep 20;28(27):4154-61
pubmed: 20713876
J Oncol Pract. 2019 Feb;15(2):67-75
pubmed: 30763199
J Gen Intern Med. 2015 May;30(5):641-50
pubmed: 25586868
CA Cancer J Clin. 2016 Nov 12;66(6):443-459
pubmed: 27618563
Qual Saf Health Care. 2010 Dec;19(6):484-9
pubmed: 21127109
JAMA Oncol. 2018 Feb 1;4(2):164-171
pubmed: 29145584
J Clin Oncol. 2018 Aug 1;36(22):2326-2347
pubmed: 29782209
J Oncol Pract. 2019 Nov;15(11):e969-e978
pubmed: 31425009
Patient. 2020 Feb;13(1):83-102
pubmed: 31456136
Am J Kidney Dis. 2013 Mar;61(3):440-9
pubmed: 23177730

Auteurs

Alex Fauer (A)

School of Nursing, University of Michigan, 400 North Ingalls St., Ann Arbor, MI, 48109, USA. alfauer@ucla.edu.
Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA. alfauer@ucla.edu.

Sung Won Choi (SW)

Medical School, University of Michigan, Ann Arbor, MI, USA.
Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.

Lauren P Wallner (LP)

Medical School, University of Michigan, Ann Arbor, MI, USA.
School of Public Health, University of Michigan, Ann Arbor, MI, USA.
Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.

Matthew A Davis (MA)

School of Nursing, University of Michigan, 400 North Ingalls St., Ann Arbor, MI, 48109, USA.
Medical School, University of Michigan, Ann Arbor, MI, USA.

Christopher R Friese (CR)

School of Nursing, University of Michigan, 400 North Ingalls St., Ann Arbor, MI, 48109, USA.
School of Public Health, University of Michigan, Ann Arbor, MI, USA.
Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH